Brainify.ai is built around a data-and-services model rather than a single diagnostic device, pairing its BREEG hardware with a Datahub spanning 2.7M patients and 430K EEGs that pharma sponsors can license to enrich clinical trials and identify placebo responders. That positions it closer to a CNS drug-development infrastructure play, competing for pharma biomarker contracts, than to a patient-facing diagnostics company like Zeto or BioSerenity.